Related Experiment Video
Updated: Mar 31, 2026

Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Antiresorptive Therapies for the Treatment of Malignant Osteolytic Bone Disease
1Department of Medicine, Cancer Institute at St. Francis Hospital, The Heart Center, 100 Port Washington Boulevard, Roslyn, NY 11576, USA.
Abstract:
Osteolytic bone disease contributes to morbidity and mortality. Antiresorptive therapies reduce the morbidity of metastatic bone disease and alter the natural progression of malignant bone pathophysiology. Several trials showed improvement in quality of life, delay of skeletal-related events, and improvement in bone pain with these agents. Evolving data suggest a role of improvement in morbidity related to other cancer therapies that have potential side effects. Early indication shows they may alter survival in a subset of patients. This article reviews data confirming the efficacy of antiresorptive agents and discusses preliminary data on preventative therapy.
More Related Videos
Related Concept Videos
Osteoclasts in Bone Remodeling
Targeted Cancer Therapies
There are several types of targeted therapies against...
Bone Remodeling
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Urinary Tract Calculi III: Medical Management

